Cutting-edge biotech Sangamo stock dives 12% after JPMorgan cites ‘growing skepticism’ in downgrade

Sangamo SGMO, +1.89%  is developing programs for a range of devastating diseases, and has valuable deals with prominent pharmaceutical companies like Gilead Sciences Inc. GILD, -0.23%  and Pfizer Inc. PFE, -0.48%  .